Mini Review
Update on Cardiovascular Benefits with Sodium Glucose Cotransporter-2 Inhibitors (SGLT-2i)
Received Date: May 13, 2019; Published Date: May 16, 2019
Abstract
The prevalence of type 2 diabetes mellitus (T2DM) has reached epidemic proportions. The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014 [1]. Approximately 90% of these patients are expected to have T2DM based on the population-based surveys in developed countries [2]. The latest estimates by the international diabetes federation project that 592 million adults (1 in 10 persons) worldwide will have DM by 2035 [3].
Signup for Newsletter
